Modernas stock surged 150% in Thursday morning trading on Wall Street, following the success of an experimental cancer vaccine, according to The Zioneer. The sharp rise comes a day after Moderna and Merck announced a successful Phase 3 trial of a personalized mRNA melanoma vaccine.
Moderna shares soared 150% in early trading Thursday on Wall Street, extending gains after the company and Merck announced a successful Phase 3 trial of a personalized mRNA melanoma vaccine. The surge outpaced the initial jump reported Wednesday evening, when The Zioneer noted the stock was already climbing on the news. The magnitude of the move—a 150% gain—reflects strong investor excitement over the potential of the experimental treatment, which targets specific tumor mutations to prevent recurrence. Moderna and Merck have not yet released additional data, and trading volumes are expected to remain high through the session.
4 developments
Source and signal
- Open-source intake